Top pick for
All rounder
How to buy ImmuPharma shares | 12.802p
Own ImmuPharma shares in just a few minutes.
ImmuPharma plc (IMM) is a leading biotechnology business based in the UK. It opened the day at 13.305p after a previous close of 13.25p. During the day the price has varied from a low of 12.6p to a high of 13.65p. The latest price was 12.802p (25 minute delay). ImmuPharma is listed on the London Stock Exchange (LSE) and employs 17 staff. All prices are listed in pence sterling.
How to buy shares in ImmuPharma
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: IMM in this case.
- Research ImmuPharma shares. The platform should provide the latest information available.
- Buy your ImmuPharma shares. It's that simple.
How has Coronavirus impacted ImmuPharma's share price?
Since the stock market crash in March caused by coronavirus, ImmuPharma's share price has had significant negative movement.
Its last market close was 14.35p, which is 10.31% down on its pre-crash value of 16p and 104.71% up on the lowest point reached during the March crash when the shares fell as low as 7.01p.
If you had bought £1,000 worth of ImmuPharma shares at the start of February 2020, those shares would have been worth £623.98 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,059.04.
ImmuPharma share price
Use our graph to track the performance of IMM stocks over time.ImmuPharma shares at a glance
Information last updated 2020-07-02.
| Open | 13.305p |
|---|---|
| High | 13.65p |
| Low | 12.6p |
| Close | 12.802p |
| Previous close | 13.25p |
| Change | -0.448p |
| Change % | -3.381% |
| Volume | 407,725 |
Information last updated 2020-07-12.
| 52-week range | 6.91p - 34p |
|---|---|
| 50-day moving average | 14.7022p |
| 200-day moving average | 13.6957p |
| Wall St. target price | 5p |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | -5.1p |
Get your first 50 trades commission free with Fineco
Fees apply. Your capital is at risk.
- Market leading platform
- No minimum deposit, no conversion fee, no monthly fee
- Your first 50 share trades are free until 30/09/2020
Share dealing platform comparison
Table: sorted by promoted deals first
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.
Is it a good time to buy ImmuPharma stock?
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
ImmuPharma price performance over time
Historical closes compared with the last close of 12.802p
| 1 week (2020-07-06) | -3.38% |
|---|---|
| 1 month (2020-06-12) | -17.54% |
| 3 months (2020-04-09) | 26.44% |
| 6 months (2020-01-13) | -18.20% |
| 1 year (2019-07-12) | 25.05% |
|---|---|
| 2 years (2018-07-13) | -41.28% |
| 3 years (2017-07-13) | -77.93% |
| 5 years (2015-07-13) | -67.38% |
ImmuPharma financials
| Revenue TTM | £77,925 |
|---|---|
| Gross profit TTM | £77,925 |
| Return on assets TTM | -54.31% |
| Return on equity TTM | -95% |
| Profit margin | 0% |
| Book value | 0.031p |
| Market capitalisation | £25.3 million |
TTM: trailing 12 months
ImmuPharma share dividends
We're not expecting ImmuPharma to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
ImmuPharma share price volatility
Over the last 12 months, ImmuPharma's shares have ranged in value from as little as 6.91p up to 34p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while ImmuPharma's is 0.6529. This would suggest that ImmuPharma's shares are less volatile than average (for this exchange).
ImmuPharma overview
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, anti-infectives, metabolism, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. The company was founded in 1999 and is headquartered in London, the United Kingdom.
Frequently asked questions
Ask an Expert